Home › Companies › GOSS

Gossamer Bio, Inc.

GOSS Rare disease Lead: Phase 3 5 Biotech Distilled articles ↓

Cardiovascular Small Molecule

Most recent annual filing: 2026-03-15

Pipeline (6 active programs)

seralutinib

GB002

Small Molecule Target: PDGFR, CSF1R, c-KIT

Pulmonary Arterial Hypertension Phase 3 inhaled Chiesi
Pulmonary Hypertension associated with Interstitial Lung Disease Phase 3 inhaled Chiesi

vardenafil

RT234

Small Molecule Target: PDE5

Pulmonary Arterial Hypertension Phase 2 inhaled Respira Therapeutics
Pulmonary Hypertension associated with Interstitial Lung Disease Phase 2 inhaled Respira Therapeutics

seralutinib

Biotech Distilled coverage (5)

2026-05-19 UPDATE: Gossamer Bio (GOSS) - The Debt Wall Comes Down, and So Does the Equity
2026-05-16 UPDATE: Gossamer Bio (GOSS) - The Zombie Files Its Q1, and a Class Action Arrives 🔒 Paid
2026-03-22 UPDATE: Gossamer (GOSS) - The Anatomy of a Biotech Death Spiral
2026-03-01 UPDATE: Gossamer Bio (GOSS) - The Enrichment Trap Springs Shut 🔒 Paid
2026-02-03 Gossamer Bio (GOSS): Scientific Deep Dive for Seralutinib 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.